Thursday, January 27, 2022 8:01:10 AM
“Dosing the first patient in our CAH trial is a landmark milestone and we are grateful for the support from the medical and patient communities who helped us reach this moment. For more than 50 years people living with CAH have had the same limited standard of care – lifelong daily steroid replacement treatment. Our investigational gene therapy offers patients a potential single-dose intervention designed to restore their body’s hormone and steroid balance by making their own cortisol and aldosterone,” said Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy. “This is the second gene therapy trial we have initiated in less than four months, and we are excited to advance this trial and our other gene therapy programs in the hope of improving patients’ lives.”
“Adults, children and families affected by CAH experience the daily burden of the disease and often, unfortunately, the side effects and morbidities associated with the current treatment regimens. As an endocrinologist, it’s incredibly exciting to reimagine a new approach to treating this disease,” added Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy. Adrenas Therapeutics, the affiliate company of BridgeBio focused on developing BBP-631 for CAH, is part of BridgeBio Gene Therapy’s portfolio.
The Phase 1/2 open-label study is designed to evaluate the safety, tolerability and pharmacodynamic activity of the company’s AAV5 gene therapy, BBP-631, in adults with classic CAH. In the initial dose-finding phase of the study, each subject will receive a single intravenous (IV) infusion. The primary outcomes of the study are safety, as well as change from baseline in endogenous cortisol levels which BBP-631 has the unique potential to restore. Change from baseline in steroid biomarkers for hydroxyprogesterone (17-OHP) levels and androstenedione (A4) levels will also be measured. Preclinical proof-of-concept data have shown the approach provides efficient and persistent delivery of functional 21-hydroxylase (21-OH) enzyme to the adrenal gland.
“We are honored to be the first site to administer gene therapy in a patient with CAH as it is a potential game-changing treatment option that targets the disease at its source,” said Kyriakie Sarafoglou, M.D., associate professor and director of the Center for Congenital Adrenal Hyperplasia at the University of Minnesota. “We are eager to see whether gene therapy can restore endogenous cortisol production, and also look forward to exploring its effect on the physiological mechanisms that regulate the hypothalamic-pituitary-adrenal axis including circadian and ultradian hormonal profiles.”
BridgeBio’s investigational AAV5 gene therapy for CAH is one of the Company’s 14 programs that are in the clinic or commercial setting for patients living with genetic diseases and cancers. Initial Phase 1/2 data readouts of the Company’s AAV5 gene therapy for CAH and the Company’s AAV9 gene therapy for Canavan disease are expected in the second half of 2022.
History.htm
Recent BBIO News
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 04/07/2024 05:15:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 10:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:13:04 PM
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 03/06/2024 04:53:56 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 10:25:14 PM
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/04/2024 09:17:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:00:28 PM
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM • GlobeNewswire Inc. • 03/04/2024 07:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:27:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:31:59 PM
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:03:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 09:06:39 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:00:10 PM
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan • GlobeNewswire Inc. • 02/07/2024 12:34:22 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2024 12:30:00 PM
- BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 02/05/2024 12:30:00 PM
- BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months • GlobeNewswire Inc. • 02/02/2024 12:00:00 PM
- Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics • PR Newswire (US) • 01/30/2024 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM